#SEOM20 Cáncer de Vejiga no músculo infiltrante: lo que el oncólogo debe saber en 2020 Javier Puente, MD, PhD Director of the Institute of Oncology Associate Professor of Medicine, Complutense University of Madrid, Spain Medical Oncology Department, GU Cancer Unit Hospital Clínico San Carlos, Madrid, Spain
19
Embed
Cáncer de Vejiga no músculo infiltrante: lo que el oncólogo ......Cáncer de Vejiga no músculo infiltrante: lo que el oncólogo debe saber en 2020 Javier Puente, MD, PhD Director
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
#SEOM20
Cáncer de Vejiga no músculo infiltrante: lo que el oncólogo debe saber en 2020
Javier Puente, MD, PhD Director of the Institute of Oncology
Associate Professor of Medicine, Complutense University of Madrid, Spain Medical Oncology Department, GU Cancer Unit
7.some urothelial carcinomas with other rare differentiation
8.small-cell carcinomas
9. sarcomatoid* urothelial carcinoma.
LVI is associated with an increased risk of pathological upstaging and worseprognosis
#SEOM20
Pathological Classification of NMIBC PATHOLOGICAL CLASSIFICATION
Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549-557. doi:10.1111/bju.14047
The 2009 TNM classification approved by the UnionInternational Contre le Cancer (UICC) was updated in 2017 (8th Edn.), but with no changes in relation to bladder tumours
PATHOLOGICAL CLASSIFICATION
Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549-557. doi:10.1111/bju.14047
The 2009 TNM classification approved by the UnionInternational Contre le Cancer (UICC) was updated in 2017 (8th Edn.), but with no changes in relation to bladder tumours
Smith AB, et al. BJU Int 2018
#SEOM20
T1 subclassification of NMIBC
Smith AB, et al. BJU Int 2018
T1 SUBCLASSIFICATION
1. The depth and extent of invasion into the lamina propria (T1 substaging) has been demonstrated to be of prognostic value in retrospective cohort studies
2. Its use is recommended by the most recent2016 World Health Organization (WHO) classification
3. The optimal system to substage T1 remains to be defined
T1m
T1e
T1 SUBCLASSIFICATION
• T1a: invasion above the muscularis mucosae vascular plexus (MM-VP)
• T1b: in the MM-VP
• T1c: beyond the MM-VP
Most studies found substage to be an important prognostic factor .
However, the T1 substage has not been adopted in clinical guidelines or classification systems for stage
The main reason has been lack of consensus among pathologists regarding the identification of the MM-VP at the invasion front of the tumor
• T1m: a single focus of lamina propria invasion ≦ 0.5 mm
• T1e: specimens showing a >0.5-mm lamina propria invasion or multiple microinvasiveareas.
#SEOM20
Pathological Classification of NMIBC
Soukup V, et al. Eur Urol 2017
PATHOLOGICAL CLASSIFICATION
Soukup, V., et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol, 2017. 72: 801.
A systematic review and meta-analysis did not show that the 2004/2016 classification outperforms the 1973 classification in prediction of recurrence and progression
- Current guidelines recommend the USE OF INTRAVESICAL BCG in some intermediate and high-risk NMIBC to reduce the risk of recurrence and progression.
EAU, AUA guidelines 2020; Herr et al,. J Urol 1979
#SEOM20
BCG is the standard of care: Current problems
- Although there is a high rate of complete response (70%) to initial therapy, most patients do not maintain response:
- 30% recurrence within 1 year - 40% progress to MIBC - 20-30% progress to metastatic disease
- Global demand for BCG is up to 2 million doses per year but…
- BCG shortage: Only few companies produce BCG for oncotherpay and export it worldwide, closures of BCG plants in 2012 and 2014, reduction of production in 2015, withdrawal of a large BCG manufacturer in 2017…
- Tumor heterogeneity
Hemdan T, et al. J Urol 2014 ; Herr et al,. J Urol 2015; Anastasiadis A, et al. Ther Adv Urol 2012
#SEOM20
Tumor heterogeneity in NMIBC
Pietzak et al. Eur Urol 2017
#SEOM20
Risk stratification NMIBC
MOLECULAR SUBTYPES (THE FUTURE)
MOLECULAR SUBTYPES (THE FUTURE)
Hedegaard J, et al. Cancer Cell 2017
#SEOM20
How to treat bladder cancer patients in the BCG shortage era?
- Optimise the use of BCG - Selecting BCG responders (ARID1A mutations, etc) - Reducing BCG dose (One-third dose vs full dose was not inferior DFS & OS) - Shorten the lengh of the BCG course? - Reduce the number of instillations per maintenance cycle